Tratamiento de la ETV

¿Sirve para algo el reposo en cama?

. Trujillo-Santos J, Perea-Milla E, Jiménez-Puente A, Sánchez-Cantalejo E, Del Toro J, Grau E, Monreal M and the RIETE Investigators. Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism: findings from the RIETE Registry. Chest 2005 May; 127(5): 1631-6.

 

La ETV en los pacientes con pesos extremos

. Barba R, Marco J, Martín-Álvarez H, Rondón P, Fernández-Capitán C, García-Bragado F, Monreal M for the RIETE Investigators. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective Registry (RIETE). J Thromb Haemost 2005 May; 3(5): 856-62.

 

Los obesos con ETV mueren menos

. Barba R, Zapatero A, Losa JE, Valdés V, Todolí JA, Di Micco P, Monreal M and the RIETE Investigators. Body mass index and mortality in patients with acute venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2008 Apr; 6(4): 595-600.

 

Escala para identificar quién va a sangrar durante la anticoagulación

. Ruiz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Sampériz AL, Monreal M and the RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008 Jul; 100(1): 26-31.

 

ETV en pacientes con una hemorragia grave reciente

. Nieto JA, Camara T, González-Higueras E, Ruiz-Giménez N, Guijarro R, Marchena PJ, Monreal M for the RIETE Investigators. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008 Nov; 100(5): 789-96.

 

¿Qué pacientes mueren por sangrado durante la anticoagulación?

. Nieto JA, Solano R, Ruiz-Ribó MD, Ruiz-Giménez N, Prandoni P, Kearon C, Monreal M and the RIETE Investigators. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2010 Jun; 8(6):1216-22.

 

La ETV en pacientes ingresados es más grave que en los pacientes que acuden de casa a Urgencias

. Maestre A, Sánchez R, Rosa V, Aujesky D, Lorenzo A, Barillari G, Monreal M and the RIETE Investigators. Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism. Findings from the RIETE Registry. Eur J Intern Med 2010 Oct; 21(5): 377-82.

 

Mortalidad los fines de semana o durante días laborables

. Lecumberri R, Soler S, del Toro J, Barba R, Rosa V, Ciammaichella M, Monreal M. Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2011 Jan; 105(1): 45-51.

 

Trombopenia por heparina

. Falvo N, Bonithon-Kopp C, Rivron-Guillot K, Todolí JA, Jiménez-Gil M, Di Micco P, Monreal M, for the RIETE Investigators. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2011 Sep; 9(9):1761-8.

 

Fiebre en los pacientes con ETV

. Barba R, Di Micco P, Blanco-Molina A, Delgado C, Cisneros E, Villalta J, Morales MV, Bura-Riviere A, Debourdeau P, Monreal M, for the RIETE Investigators. Fever and deep venous thrombosis. Findings from the RIETE Registry. Thromb Thrombolysis. 2011 Oct; 32(3): 288-92.

 

La ETV en pacientes con enfermedad pulmonar crónica

. Bertoletti L, Quenet S, Mismetti P, Hernández L, Martín-Villasclaras JJ, Tolosa C, Valdés M, Barrón M, Todolí J, Monreal M and the RIETE Investigators. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012 Apr; 39(4): 862-8.

 

Escala para identificar a los pacientes que harán una hemorragia mortal

. Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Giménez N, Fernández-Capitán C, Valero B, Tiberio G, Bura-Riviere A, Monreal M for the RIETE Investigators. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thromb Res 2013 Aug; 132(2): 175-9.

 

Mortalidad de las recidivas y las hemorragias en función del tiempo

. Lecumberri R, Alfonso A, Jiménez D, Fernández Capitán C, Prandoni P, Wells PS, Vidal G, Barillari G, Monreal M, and the RIETE Investigators. Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost 2013 Sept; 110(4): 834-43.

 

El número de plaquetas predice la evolución clínica

. Di Micco P, Ruiz-Giménez N, Nieto JA, Aujesky D, Del Molino F, Valle R, Barrón M, Maestre A, Monreal M, and the RIETE investigators. Platelet count and outcome in patients with acute venous thromboembolism. Thromb Haemost 2013 Oct; 110(5): 1025-34.

 

La ETV no es igual en hombres y mujeres

. Blanco-Molina A, Enea I, Gadelha T, Tufano A, Bura-Riviere A, Di Micco P, Bounameaux H, González J, Villalta J, Monreal M. Sex differences in patients receiving anticoagulant therapy for venous thromboembolism.Medicine (Baltimore). 2014 Oct; 93(17): 309-17.

 

La ETV en pacientes con antiagregantes y anticoagulantes

. Tzoran I, Brenner B, Sakharov G, Trujillo-Santos J, Lorenzo A, Madridano O, López-Sáez JB, Monreal M and RIETE investigators. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy. Eur J Intern Med 2014 Nov; 25(9): 821-5.

 

Comparación de 4 escalas para identificar el riesgo de hemorragia

. Piovella C, Dalla Valle F, Trujillo-Santos J, Pesavento R, López L, Font L, Valle R, Nauffal D, Monreal M, Prandoni P and the RIETE Investigators.Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism. Findings from the RIETE Registry. Intern Emerg Med 2014 Dec; 9(8): 847-52.

 

Fondaparinux en el tratamiento de la ETV

. Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, López-Jiménez L, Falgá C, García-Bragado F, Piovella C, Prandoni P, Monreal M and the RIETE Investigators. Fondaparinux in the initial and long-term treatment of venous thromboembolism. Thromb Res 2015 Feb; 135(2): 311-7.

 

¿Durante cuánto tiempo tratamos la ETV?

. Ageno W, Sampériz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M and the RIETE investigators. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 2015 Apr; 135(4): 666-72.

 

¿Cómo tratamos la ETV?

. Mahé I, Sterpu R, Bertoletti L, López-Jiménez L, Mellado Joan M, Trujillo-Santos J, Ballaz A, Hernández Blasco LM, Marchena PJ, Monreal M and the RIETE investigators. Long-Term anticoagulant therapy of patients with venous thromboembolism. What are the practices? PLoS One 2015 Jun 15; 10(6):e0128741.

 

¿Cómo tratan la ETV en Italia?

. Dentali F, Di Micco G, Giorgi Pierfranceschi M, Gussoni G, Barillari G, Amitrano M, Fontanella A, Lodigiani C, Guida A, Visonà A, Monreal and Di Micco P. Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Ann Med 2015 Sep 30: 1-9.

 

Recuento de plaquetas y hemorragia durante el tratamiento

. Giorgi-Pierfranceschi M, Di Micco P, Cattabiani C, Guida A, Pagán B, Morales MV, Salgado E, Suriñach JM, Tolosa C, Monreal M and the RIETE Investigators. Platelet count and major bleeding in patients receiving vitamin K antagonists for acute venous thromboembolism, Findings from real world clinical practice. Medicine (Baltimore) 2015 Nov; 94(47): e1915.

 

Recidivas de ETV durante el tratamiento

. Lobo JL, Jiménez D, Orue MT, Grau E, Naufall D, Madridano O, Monreal M and the RIETE Investigators. Recurrent venous thromboembolism during coumarin therapy. Data from the computerised Registry of patients with venous thromboembolism. Brit J Haematol 2007 Aug; 138 (3): 400-3.

 

Las hemorragias graves se asocian a más muerte

. Prandoni P, Trujillo-Santos J, Sánchez-Cantalejo E, Dalla Valle F, Piovella C, Pesavento R, Nieto Rodríguez JA, Monreal M for the RIETE Group. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost 2010 Nov; 8(11): 2575-7.

 

¿Qué ocurre cuando el d-dimero es negativo?

. Soto MJ, Grau E, Gadelha T, Palareti G, Bounameaux H, Villalta J, Monreal M and the RIETE investigators. Clinical significance of negative D-dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry. J Thromb Haemost 2011 Feb; 9(2): 407-10

 

¿Isquemia arterial tras una ETV?

. Madridano O, Del Toro J, Lorenzo A, Martín M, Gómez Cerezo J, Hernández L, Prandoni P, Monreal M; RIETE Investigators. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. J Vasc Surg Venous Lymphat Disord. 2015 Apr;3(2):135-141.e1. doi: 10.1016/j.jvsv.2014.11.002. Epub 2015 Mar 13.

 

Share This